It's a great time to be a doctor treating patients with heart failure, given the development of 2 fantastic new treatments within the space of 5 years, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
It's a great time to be a doctor treating patients with heart failure, what with the development of 2 fantastic new treatments within the space of 5 years, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
The American Journal of Managed Care®(AJMC®): EMPEROR-Reduced results published in The New England Journal of Medicine reported a 6% difference in the hazard ratio in the outcomes for patients with diabetes and those without diabetes; the paper characterized the effect as basically the same. Do you agree?
Dr. McMurray:Absolutely. We saw this in DAPA-HF, completely consistent effects in patients with and without diabetes. Maybe this has been the problem, maybe cardiologists are still thinking, although this is rather old fashioned thinking, that these are treatments only for diabetes. They're not. They are a treatment for diabetes, but they are also a treatment for heart failure. We've repurposed SGLT 2 inhibitors to be treatment for heart failure. It's like Sildenafil. It was it introduced as a treatment for erectile dysfunction. But we cardiologists use it today as a treatment for pulmonary hypertension. It's same molecule, but 2 completely different indications. So yes, useful glucose lowering therapy for diabetes. This is our drug. This is a heart failure drug, and we can do a huge amount of good for our patients.
AJMC®: Results from DAPA-HF found dapagliflozin could prevent diabetes in individuals with prediabetes. Does empagliflozin show potential diabetes prevention effects in this population? Can you discuss the debate around preventing type 2 diabetes with a drug?
Dr. McMurray: That is correct. We did show reduction in new onset diabetes amongst those patients who didn't have diabetes at baseline in DAPA-HF. These same analyses have not been presented for EMPEROR-Reduced. So we don't know if that's the case with empagliflozin, but I would anticipate broadly similar effects because these drugs are similar in structure and act in the same way. But we haven't seen those data and we only know that for dapagliflozin at the moment.
I don't think there is much debate about it. It's a great additional benefit to have. If you're a patient with heart failure, the last thing you want to do is to develop diabetes as well. So that is what I would call a bonus of this therapy. It does all the good things I mentioned earlier: improves symptoms, reduces hospitalization, reduces mortality. We know it also reduces worsening renal function. And now this is an additional benefit: it reduces new onset diabetes. So little controversy, no discussion, great bonus effects in patients who don't have diabetes at the moment, who are at very high risk of developing diabetes that's maybe not often realized. Heart failure is an extremely diabetogenic disease. It's great that we can reduce or delay the development of new onset diabetes.
AJMC®: Do you have any final thoughts you'd like to share?
Dr. McMurray: It's fantastic to be in this new era of heart failure therapy and in the space of 5 years to have 2 fantastic new treatments completely complimentary and additive to the other therapies that we have. It's a great time to be a doctor treating patients with heart failure. And hopefully it's a great time for patients with heart failure because we now have so much more to offer them if they get the therapy. So the key from here on is implementation. The way the trials have given our colleagues the evidence, we need everybody now to put that evidence into practice.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More